SCHEMBL4929083

SCHEMBL4929083

O=C(Nc1ccccc1)c1ncsc1NC(=O)c1c(Cl)cc(Cl)cc1Cl

nearest known ligand 0.49

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PTPRC P08575 1/20 0.49
GPR27 Q9NS67 1/20 0.46
JAK2 O60674 3/20 0.44
TYK2 P29597 3/20 0.44
HSD17B13 Q7Z5P4 2/20 0.43
KDM4E B2RXH2 1/20 0.43
GRM1 Q13255 1/20 0.42
PTGS2 P35354 1/20 0.42
CYP3A4 P08684 1/20 0.42
JAK1 P23458 1/20 0.42
MEN1 O00255 1/20 0.41
MAPT P10636 1/20 0.41
RAB9A P51151 1/20 0.41
KMT2A Q03164 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
F12 P00748 1/20 0.41
ATR Q13535 2/20 0.41
NAMPT P43490 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4931432 0.88 PTPRC (0.46) PTPRCJAK2TYK2HSD17B13GRM1
SCHEMBL4931447 0.84 NPC1 (0.52) JAK2TYK2JAK1MEN1RAB9A
SCHEMBL4933912 0.84 MEN1 (0.49) PTPRCHSD17B13MEN1MAPTRAB9A
SCHEMBL4931435 0.84 ANO1 (0.40) PTPRCHSD17B13KDM4EMEN1RAB9A
SCHEMBL4152879 0.82 PTPRC (0.61) PTPRCGPR27JAK2TYK2PTGS2
SCHEMBL4925457 0.81 MAPT (0.51) MEN1MAPTRAB9AKMT2ANPSR1
SCHEMBL4934125 0.80 MAPKAPK2 (0.52) MEN1RAB9AKMT2A
SCHEMBL14154771 0.78 GHSR (0.43) PTPRCMEN1MAPTRAB9AKMT2A
SCHEMBL2826806 0.77 ATR (0.50) KDM4EMEN1MAPTRAB9AKMT2A
SCHEMBL4935840 0.76 KMT2A (0.52) JAK2TYK2KDM4ECYP3A4JAK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080167309-A1 Pharmaceutical Compounds ASTEX THERAPEUTICS, LTD. (UK) 2008-07-10 US claimed
EP-1781647-A2 THIAZOLE AND ISOTHIAZOLE DERIVATIVES AS PROTEIN KINASE INHIBITORS Astex Therapeutics Limited (GB) 2007-05-09 EP claimed
WO-2006008545-A2 THIAZOLE AND ISOTHIAZOLE DERIVATIVES AS PROTEIN KINASE INHIBITORS ASTEX THERAPEUTICS LIMITED (GB) 2006-01-26 WO claimed
US-20080167309-A1 Pharmaceutical Compounds ASTEX THERAPEUTICS, LTD. (UK) 2008-07-10 US disclosed
US-20080167309-A1 Pharmaceutical Compounds ASTEX THERAPEUTICS, LTD. (UK) 2008-07-10 US disclosed
US-20080167309-A1 Pharmaceutical Compounds ASTEX THERAPEUTICS, LTD. (UK) 2008-07-10 US disclosed
EP-1781647-A2 THIAZOLE AND ISOTHIAZOLE DERIVATIVES AS PROTEIN KINASE INHIBITORS Astex Therapeutics Limited (GB) 2007-05-09 EP disclosed
WO-2006008545-A2 THIAZOLE AND ISOTHIAZOLE DERIVATIVES AS PROTEIN KINASE INHIBITORS ASTEX THERAPEUTICS LIMITED (GB) 2006-01-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080167309-A1 Pharmaceutical Compounds CCNO, CDK2, CDK1 PTPRC 1357/4885GPR27 3494/4885JAK2 148/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.